Welcome to our dedicated page for Qiagen news (Ticker: QGEN), a resource for investors and traders seeking the latest updates and insights on Qiagen stock.
News about QIAGEN N.V. (QGEN) centers on its role as a Netherlands-based Sample to Insight company serving life sciences and molecular diagnostics customers worldwide. This news feed aggregates corporate announcements, product updates, regulatory milestones and financial communications directly related to QGEN.
Readers can follow updates on QIAGEN’s five growth pillars: Sample technologies, QIAstat-Dx syndromic testing, QIAcuity digital PCR, QIAGEN Digital Insights (QDI) bioinformatics and QuantiFERON latent tuberculosis testing. Company news often highlights launches and enhancements of automation systems such as QIAcube Connect, QIAsymphony Connect, QIAsprint, QIAmini and EZ2 Connect Fx, as well as new kits like the EZ2 DNA Investigator Sep&Prep Kit for forensic applications.
Regulatory and clinical diagnostics news includes items such as CE-IVDR certification for QIAstat-Dx panels in Europe, U.S. FDA clearance for QIAstat-Dx Rise, and expansions of test menus for respiratory, gastrointestinal and central nervous system infections. These announcements show how QIAGEN positions its platforms in infectious disease and syndromic testing.
Investors and analysts can also track financial and capital markets developments, including quarterly earnings releases furnished on Form 6-K, outlook updates, and capital return actions such as synthetic share repurchase plans that combine direct capital repayments with reverse stock splits. Strategic moves, for example the agreement to acquire Parse Biosciences to expand into single-cell analysis, are another recurring theme in QGEN news.
For users interested in precision oncology, bioinformatics and AI-enabled solutions, QIAGEN’s news includes information on partnerships, new software capabilities within QDI, and integrated Sample to Insight workflows. Bookmark this page to access an organized stream of QGEN-related announcements spanning products, diagnostics, automation, bioinformatics and investor communications.
QIAGEN N.V. (NYSE: QGEN) has formed a strategic partnership with Verogen Inc. to enhance next-generation sequencing (NGS) tools for human identification workflows. This agreement grants QIAGEN global distribution rights for Verogen's products and involves collaboration on forensically validated NGS workflows. The partnership aims to provide laboratories with comprehensive solutions, optimizing QIAGEN’s sample prep automation alongside Verogen’s innovative NGS capabilities. This collaboration is expected to drive the adoption of NGS technology in forensic applications, improving insights from casework samples.
QIAGEN N.V. (NYSE: QGEN) announced a partnership with Verogen, enhancing its offerings in human identification workflows. This collaboration allows QIAGEN to distribute Verogen's sequencing solutions, including the ForenSeq assay and MiSeq FGx sequencing system, globally. Both companies will develop forensically validated workflows that combine their products and expertise. This partnership aims to accelerate the adoption of next-generation sequencing (NGS) in forensics, providing laboratories with improved tools for human identification. Financial terms were not disclosed.
QIAGEN (NYSE: QGEN) has launched the QIAprep CRISPR Kit and CRISPR Q-Primer Solutions, enhancing speed and efficiency in analyzing edited genetic material. This launch targets the booming CRISPR technology sector, crucial for gene editing and biomedical research. The new products facilitate a sensitive, all-in-one approach to analyze gene editing effects, reducing experimental time significantly. These solutions support various cell culturing methods and can be customized for targeted applications, potentially accelerating breakthroughs in areas like cancer therapy and drug development.
QIAGEN N.V. (QGEN) has launched an expanded scope of companion diagnostic claims for the therascreen KRAS RGQ PCR Kit, following FDA approval. This kit aids in identifying non-small cell lung cancer (NSCLC) patients eligible for Amgen's LUMAKRASTM treatment, targeting the KRAS G12C mutation, present in up to 13% of NSCLC cases. This approval marks a significant milestone in precision medicine, enhancing QIAGEN's therascreen portfolio and expanding testing availability through its Day-One Lab Readiness program.
QIAGEN N.V. announced a global collaboration with Mirati Therapeutics to develop a tissue-based KRAS companion diagnostic for cancers with the KRASG12C mutation, focusing initially on non-small cell lung cancer (NSCLC). This initiative expands QIAGEN's existing therascreen KRAS testing portfolio and leverages the company's decade-long expertise in companion diagnostics. QIAGEN holds a strong position in Precision Medicine and has ongoing collaborations with over 25 companies for companion diagnostic tests, indicating a robust pipeline for future product development.
QIAGEN N.V. (NYSE: QGEN) announced the formation of a Scientific Advisory Board to evaluate market and technology trends affecting its growth in Life Sciences and Molecular Diagnostics. The Board features industry leaders such as Dr. Peter Kaspar and Prof. Patrice Nordmann, chaired by Prof. Dr. Ross L. Levine. Additionally, QIAGEN will hold a virtual Annual General Meeting on June 29, 2021, addressing sustainability within an ESG framework and proposing re-elections for seven Supervisory Board members, alongside CEO Thierry Bernard and CFO Roland Sackers.
QIAGEN N.V. has received Emergency Use Authorization (EUA) from the FDA for its QIAreach® Anti-SARS-CoV-2 Total Test. This portable antibody testing device delivers results in about 10 minutes and can process up to 32 tests per hour using a digital eHub. The test has a sensitivity of 93.85% and a specificity of 97.83%. Developed with Ellume, this test aims to aid in monitoring immunity against COVID-19. QIAGEN also launched the QuantiFERON SARS-CoV-2 test for detecting T-cell responses. The new device enhances the efficiency of serological testing in healthcare settings.
QIAGEN N.V. (NYSE: QGEN) reported a 52% increase in net sales for Q1 2021, reaching $567.2 million. This surpassed the forecast of at least 45% growth. Adjusted earnings per share rose 94% to $0.66, exceeding the expected range of $0.60-0.62. The company's strong performance was attributed to a 16% growth in non-COVID product sales, making up 64% of total sales. QIAGEN also expanded its non-COVID portfolio and is positioned for sustainable growth beyond the pandemic.
QIAGEN N.V. (NYSE: QGEN) is set to launch the EZ2 Connect product line, an advanced automated sample-processing platform designed for biomedical research, forensics, and clinical diagnostics. Utilizing pre-filled cartridges and magnetic bead technology, it processes up to 24 samples in 20 minutes. The platform expands upon the successful EZ1 series, with applications in clinical diagnostics and forensics, and plans to introduce the EZ2 Connect MDx for molecular diagnostics in early 2022. The platform enhances lab automation, safety, and efficiency, backed by significant previous product installations.
QIAGEN and DiaSorin announced the launch of the LIAISON® LymeDetect® Assay, enhancing early detection of Lyme Borreliosis. This assay integrates antibody detection with a unique interferon-gamma release test, achieving a sensitivity of 74% within 21 days, significantly higher than the 49% of existing methods. With a specificity of 100%, it aims to address the critical diagnostic gap and may reduce healthcare costs through earlier treatment. The collaboration leverages both companies' strengths, with DiaSorin managing commercialization while they co-develop the product.